Scholarlink

Objective <p>This study aims to investigate the clinical value of miR-1307-5p in acute coronary syndrome (ACS) patients and its role in human umbilical vein endothelial cells (HUVECs).</p> Methods <p>Enrollment consisted of 124 ACS cases and 124 controls. Reverse transcription quantitative real-time PCR (RT-qPCR) was used to measure the miR-1307-5p and proviral integration site for Moloney murine leukemia virus 3 (PIM3) levels in serum samples, and the receiver operating characteristic (ROC) curve was utilized to assess the diagnostic utility of miR-1307-5p. ACS cell model was established using hypoxia/reoxygenation (H/R). enzyme-linked immunosorbent assay (ELISA) was employed to detect the von Willebrand factor (vWF), heart-type fatty acid-binding protein (H-FABP), tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and IL-8 in serum and HUVECs. Apoptosis was analyzed by flow cytometry, while cell viability was evaluated through Cell Counting Kit-8 (CCK8) assay. The interaction between miR-1307-5p and PIM3 was validated via dual-luciferase reporter (DLR) and RNA immunoprecipitation (RIP) experiments.</p> Results <p>miR-1307-5p is significantly downregulated in ACS patients’ serum and effectively distinguishes controls from ACS patients. It also shows negative correlations with vWF, H-FABP, TNF-α, IL-6, and IL-8. miR-1307-5p directly targets PIM3. Upregulating miR-1307-5p enhances HUVEC viability and suppresses apoptosis. Furthermore, this intervention alleviates endothelial injury and reduces inflammation. Notably, PIM3 overexpression reversed these protective effects of miR-1307-5p.</p> Conclusion <p>Reduced serum miR-1307-5p expression holds promise as a potential diagnostic biomarker for ACS. Upregulation of miR-1307-5p alleviates endothelial dysfunction and inflammation by targeting PIM3, suggesting that the miR-1307-5p/PIM3 axis represents a potential therapeutic target for ACS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

miR-1307-5p mediates endothelial dysfunction and inflammation induced by acute coronary syndrome by targeting PIM3

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月9日

查看全文
  • ChangMing Jin,
  • BaoBin Sun,
  • XiaoHong Li,
  • Hao Chen,
  • Tao Zhang

摘要

Objective

This study aims to investigate the clinical value of miR-1307-5p in acute coronary syndrome (ACS) patients and its role in human umbilical vein endothelial cells (HUVECs).

Methods

Enrollment consisted of 124 ACS cases and 124 controls. Reverse transcription quantitative real-time PCR (RT-qPCR) was used to measure the miR-1307-5p and proviral integration site for Moloney murine leukemia virus 3 (PIM3) levels in serum samples, and the receiver operating characteristic (ROC) curve was utilized to assess the diagnostic utility of miR-1307-5p. ACS cell model was established using hypoxia/reoxygenation (H/R). enzyme-linked immunosorbent assay (ELISA) was employed to detect the von Willebrand factor (vWF), heart-type fatty acid-binding protein (H-FABP), tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and IL-8 in serum and HUVECs. Apoptosis was analyzed by flow cytometry, while cell viability was evaluated through Cell Counting Kit-8 (CCK8) assay. The interaction between miR-1307-5p and PIM3 was validated via dual-luciferase reporter (DLR) and RNA immunoprecipitation (RIP) experiments.

Results

miR-1307-5p is significantly downregulated in ACS patients’ serum and effectively distinguishes controls from ACS patients. It also shows negative correlations with vWF, H-FABP, TNF-α, IL-6, and IL-8. miR-1307-5p directly targets PIM3. Upregulating miR-1307-5p enhances HUVEC viability and suppresses apoptosis. Furthermore, this intervention alleviates endothelial injury and reduces inflammation. Notably, PIM3 overexpression reversed these protective effects of miR-1307-5p.

Conclusion

Reduced serum miR-1307-5p expression holds promise as a potential diagnostic biomarker for ACS. Upregulation of miR-1307-5p alleviates endothelial dysfunction and inflammation by targeting PIM3, suggesting that the miR-1307-5p/PIM3 axis represents a potential therapeutic target for ACS.